Geron Corporation (GERN)


Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Geron Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) of the March 23, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. 

If you invested in Geron stock or options between March 19, 2018 and September 26, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Geron common stock between March 19, 2018 and September 26, 2018 (the “Class Period”). The case, Tollen v. Geron Corporation et al., No. 3:20-cv-00547 was filed on January 23, 2020 and has been assigned to Judge William Alsup.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the spleen response rate, which measured the reduction in spleen swelling, and (2) a composite of various symptoms called the Total Symptom Score (TSS). In order for IMbark to succeed, patients in the study needed to show at least a 35% reduction in spleen volume and a minimum 50% reduction in TSS.

On the morning of March 27, 2018, Adam Feuerstein, a veteran biotech journalist, published an article on STAT News, an online life sciences publication, entitled “The top-performing biotech stock this year has surged on flimsy data.” In the article, Feuerstein called out Geron and Scarlett for intentionally misleading the market with their statements on March 16 and March 19, 2018.

On this news, the Company's stock price fell from $5.98 per share on March 26, 2018 to $5.15 per share on March 27, 2018: a $0.83 or 13.88% drop. 

Then, on September 27, 2018, the Company finally admitted that IMbark was a failure. The IMbark study showed only a 10% decrease in spleen volume, when 35% or more was required for success, and a 32% reduction in Total Symptom Score, when at least 50% was needed. The same day the full results were finally disclosed, Adam Feuerstein published another article on STAT News concerning Geron. The article stated in relevant part: “Back in March, Geron CEO John Scarlett ignited a steep run higher in the stock price with a suggestion, uttered on a conference call, that imetelstat was prolonging survival in patients with the bone marrow disorder myelofibrosis.” Feuerstein noted in the article that “Geron raised $84 million through highly dilutive stock sales in the second quarter,” ultimately concluding, “[t]aking advantage of the hyped-up stock price earlier this year was a fiscally smart move, although that’s small consolation to shareholders left holding the bag.”

On this news, the Company's stock price fell from $2.31 per share on September 27, 2018 to $1.76 per share on September 28, 2018: a $0.45 or 23.81% drop.

Contact us

Geron Corporation (GERN)

Loading captcha, please wait...

* The submission of this form does not create an attorney-client relationship.

Details

Filed on 01/31/2020

Ticker NASDAQ: GERN

Lead Plaintiff Deadline 03/23/2020

36 days remaining

Office

685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331

Counsel

Richard W. Gonnello rgonnello@faruqilaw.com Phone (212) 983-9330 Fax (212) 983-9331

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Delaware

3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania